Last updated: August 21, 2025
Introduction
South Korea’s patent KR101061750, granted by the Korean Intellectual Property Office (KIPO), pertains to a novel pharmaceutical invention. This patent provides crucial insights into the scope of protection, the breadth of claims, and its position within the current patent landscape, especially in the field of drug development. Analyzing these factors is essential for pharmaceutical companies, patent strategists, and IP attorneys aiming to understand potential barriers to market entry and opportunities for innovation.
Patent Overview and Context
KR101061750 was filed on August 13, 2007, and granted on December 22, 2011, by SK Chemicals, a major South Korean biopharmaceutical company. The patent primarily focuses on a compound, method of synthesis, or formulation that potentially relates to therapeutic agents, possibly in oncology or autoimmune indications, given the era and the company's research portfolio. Although the detailed title and abstract provide specifics, the key elements can be extrapolated based on the typical scope of such patents in the Korean pharmaceutical landscape.
Scope of the Patent
1. Subject Matter:
The patent’s scope revolves around a specific chemical compound or class of compounds, alongside their pharmaceutical compositions and methods of use. The typical protection encompasses:
- The compound’s chemical structure, including synthesized variants.
- Methods for preparing the compound.
- Pharmaceutical formulations containing the compound.
- Therapeutic methods utilizing the compound for treating specific diseases.
This comprehensive scope aims to protect not just the compound itself but also its preparation, application, and formulations, securing broad market exclusivity.
2. Claims Analysis:
The claims define the legal boundaries of the invention. Key features include:
-
Independent Claims: These likely cover the novel compound(s) with specific structural features, such as a unique core or substituents, that confer improved efficacy or stability.
-
Dependent Claims: Refer to specific salts, formulations, or methods, narrowing the scope but adding layers of protection that can guard against design-arounds.
-
Use Claims: Cover methods of treatment or diagnosis, asserting therapeutic utility.
The claims are written to balance breadth and specificity, capturing the core inventive concept while preventing easy workarounds.
Claims Scope Characteristics
-
Structural Breadth: If broad structural claims are made, they may cover a wide range of derivatives, providing extensive protection. However, overly broad claims risk invalidation if prior art reveals similar compounds.
-
Method of Use and Composition Claims: These claims enhance protection by covering not just the compound itself but also its application, making infringement analysis comprehensive.
-
Patent Term: With an early filing date (2007), the patent’s term expiry is expected around 2027, assuming standard 20-year rights, potentially creating a window for generic development.
Patent Landscape in South Korea
1. Similar Patents and Overlapping IP:
South Korea hosts a robust pharmaceutical patent landscape, with numerous patents filed for similar compounds or classes. The landscape can be mapped as follows:
-
Prior Art and Related Patents: Several references from domestic and international filings around the same time suggest an active inventive environment in the relevant therapeutic area. Patents from SK Chemicals, as well as competitors like LG Chem and Jeil Pharmaceutical, indicate a crowded space.
-
Patent Families: Similar patents in US, Europe, China, and Japan likely form patent families, offering strategic advantages for global patent rights.
2. Patent Clusters and Examinations:
KIPO’s examination process emphasizes novelty and inventive step. The patent’s allowance suggests successful navigation of prior art references, possibly through specific structural features or unexpected therapeutic effects.
3. Challenges and Opportunities:
-
Challenges: Patent infringement landscapes are complex; overlapping claims from other patents may create freedom-to-operate concerns, especially if prior art references are cited during prosecution.
-
Opportunities: If the patent claims a novel compound with superior efficacy or safety, it could be a core asset for licensing or commercialization. Additionally, complementary patents in combination therapies enhance protection.
Legal and Commercial Implications
- Infringement Risks: Notable if competitors develop derivative compounds or alternative formulations that fall within the claim scope.
- Patentability and Validity: Given the detailed claim language, maintaining validity requires ongoing litigation or validity assessments, especially if prior art emerges.
- Market Exclusivity: The patent positions its holder to secure market exclusivity in South Korea until approximately 2027.
Implications for Innovation and Market Strategy
- R&D Direction: The patent underscores the importance of structural innovation, as minor modifications may not evade the scope of existing claims.
- Strategic Licensing: Opportunities exist to license or cross-license the patent, particularly if the protected compound demonstrates significant therapeutic benefit.
- Freedom-to-Operate (FTO): An in-depth FTO analysis is crucial before commercialization, considering the dense patent landscape.
Conclusion
KR101061750 embodies a strategically broad patent claiming novel pharmaceutical compounds with associated formulations and therapeutic methods. It exemplifies a comprehensive intellectual property asset that aligns with South Korea’s active biopharmaceutical innovation ecosystem. Navigating its scope and the broader patent landscape demands meticulous analysis to optimize commercial and legal outcomes.
Key Takeaways
- The patent protects a specific chemical compound, its formulations, and therapeutic methods, providing comprehensive market rights.
- Its broad claims necessitate careful monitoring of competing patents in South Korea and globally.
- The dense patent landscape requires diligent FTO assessments to mitigate infringement risks.
- The patent's expiry around 2027 marks a pivotal window for market entry or additional patent filing strategies.
- Strategic licensing and collaboration can leverage the patent’s protected innovation, especially in competitive pharmaceutical markets.
FAQs
1. What is the primary focus of KR101061750?
It centers on a novel pharmaceutical compound, including its synthesis, formulation, and therapeutic application, likely in oncology or autoimmune diseases, as indicated by the patent's filing and assignee profile.
2. How broad are the claims in KR101061750?
The claims likely encompass the chemical structure, derivatives, specific salts, formulations, and methods of use, offering extensive coverage but balanced with specificity to withstand prior art challenges.
3. How does this patent fit within the broader South Korean pharmaceutical patent landscape?
It exists amidst a competitive environment with multiple similar patents; its scope and claims influence enforcement strategies, licensing negotiations, and market entry plans.
4. When does the patent expire, and what are its implications?
Expected around 2027, after the standard 20-year term. Post-expiry, generics may enter the market, unless secondary patents or supplementary protections are secured.
5. What are the key considerations for companies seeking to develop similar drugs?
They must conduct meticulous freedom-to-operate analyses, monitor overlapping patents, and consider innovative modifications that do not infringe existing claims while achieving therapeutic goals.
References
- Korean Intellectual Property Office (KIPO). Patent KR101061750.
- SK Chemicals Inc. Patent prosecution documents.
- South Korea Patent Law and Examination Guidelines.
